What is the official website of Springer Health+ India ?

The official website of Springer Health+ India is https://springerhealthplus.com/.

What is Springer Health+ India's cybersecurity risk score?

Springer Health+ India has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Springer Health+ India experienced?

According to Rankiteo, Springer Health+ India currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Springer Health+ India been affected by any supply chain cyber incidents ?

According to Rankiteo, Springer Health+ India has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Springer Health+ India have SOC 2 Type 1 certification ?

According to Rankiteo, Springer Health+ India is not certified under SOC 2 Type 1.

Does Springer Health+ India have SOC 2 Type 2 certification ?

According to Rankiteo, Springer Health+ India does not hold a SOC 2 Type 2 certification.

Does Springer Health+ India comply with GDPR ?

According to Rankiteo, Springer Health+ India is not listed as GDPR compliant.

Does Springer Health+ India have PCI DSS certification ?

According to Rankiteo, Springer Health+ India does not currently maintain PCI DSS compliance.

Does Springer Health+ India comply with HIPAA ?

According to Rankiteo, Springer Health+ India is not compliant with HIPAA regulations.

Does Springer Health+ India have ISO 27001 certification ?

According to Rankiteo,Springer Health+ India is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Springer Health+ India operate in ?

Springer Health+ India operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Springer Health+ India have ?

Springer Health+ India employs approximately None employees people worldwide.

Does Springer Health+ India own any subsidiaries ?

Springer Health+ India presently has no subsidiaries across any sectors.

How many LinkedIn followers does Springer Health+ India have ?

Springer Health+ India's official LinkedIn profile has approximately 1,227 followers.

What is the NAICS classification code for Springer Health+ India ?

Springer Health+ India is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Springer Health+ India have a Crunchbase profile ?

No, Springer Health+ India does not have a profile on Crunchbase.

Does Springer Health+ India have a LinkedIn profile ?

Yes, Springer Health+ India maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/springer-healthplus-india.

How many cybersecurity incidents has Springer Health+ India experienced ?

As of July 23, 2026, Rankiteo reports that Springer Health+ India has not experienced any cybersecurity incidents.

How many peer or competitor companies does Springer Health+ India have ?

Springer Health+ India has an estimated 5,710 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

SHI

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Springer Health+ India Vendor Cyber Rating & Cyber Score

springerhealthplus.com

Add Your Compliance Badge

Since 1982, Springer Health+ has delivered trusted healthcare education and communications. Medical progress is more than just science, and with people at the core of everything we do, our expertise delivers information that is trusted worldwide. We are a forward-thinking, diverse agency specialising in medical communications and digital engagement. Our mission is to help the medical community not just keep up with science but move it forward. Springer Health + is part of Springer Nature.

SHI A.I CyberSecurity Scoring

Scoring History

SHI

Springer Health+ India CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

SHI Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for SHI

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Springer Health+ India in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Springer Health+ India in 2026.

Incident Types SHI vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Springer Health+ India in 2026.

Incident History - SHI (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Springer Health+ India Subsidiaries

Parent Company

SHI

Pharmaceutical Manufacturing

Website: https://springerhealthplus.com/

Company Size: 201-500 employees

No subsidiary data available for this company.

Loading…

Springer Health+ India Similar Companies

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Loading…

NEWS

Springer Health+ India CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 28, 2026 08:00 AM

Springer Nature Announces Leadership Transition in India

Springer Nature today announced a leadership transition within its India business as part of the company's ongoing efforts to strengthen its...

Read Article

October 31, 2025 07:00 AM

Springer Nature honours Indian editors at Journal Development Symposium 2025. Brings Together Leading Editors and Publishing Experts to Shape the Future of Research Integrity and AI in Scholarly Communication

The day long Journal Development Symposium 2025, organised by Springer Nature, brought together over 100 journal editors,...

Read Article

October 27, 2023 07:00 AM

IoT empowered smart cybersecurity framework for intrusion detection in internet of drones | Scientific Reports

The proposed system effectively detects cyber-attacks in drone networks by leveraging deep learning and machine learning techniques.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-61246

SUMMARY

Vulnerability in the Oracle Platform Security for Java product of Oracle Fusion Middleware (component: Centralized Thirdparty Jars). Supported versions that are affected are 12.2.1.4.0 and 14.1.2.0.0. Easily exploitable vulnerability allows low privileged attacker with network access via HTTP to compromise Oracle Platform Security for Java. Successful attacks of this vulnerability can result in takeover of Oracle Platform Security for Java. CVSS 3.1 Base Score 8.8 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H).

Published

Date2026-07-22

Updated

Date2026-07-22

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://www.oracle.com/security-alerts/cpujul2026.html

CVE-2026-60455

SUMMARY

Published

Date2026-07-22

Updated

Date2026-07-22

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://www.oracle.com/security-alerts/cpujul2026.html

CVE-2026-60439

SUMMARY

Published

Date2026-07-22

Updated

Date2026-07-22

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://www.oracle.com/security-alerts/cpujul2026.html

CVE-2026-60373

SUMMARY

Published

Date2026-07-22

Updated

Date2026-07-22

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://www.oracle.com/security-alerts/cpujul2026.html

CVE-2026-60372

SUMMARY

Vulnerability in the Oracle Platform Security for Java product of Oracle Fusion Middleware (component: Centralized Thirdparty Jars). Supported versions that are affected are 12.2.1.4.0 and 14.1.2.0.0. Easily exploitable vulnerability allows unauthenticated attacker with network access via HTTP to compromise Oracle Platform Security for Java. Successful attacks of this vulnerability can result in takeover of Oracle Platform Security for Java. CVSS 3.1 Base Score 9.8 (Confidentiality, Integrity and Availability impacts). CVSS Vector: (CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H).

Published

Date2026-07-22

Updated

Date2026-07-22

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

3.9

REFERENCES

https://www.oracle.com/security-alerts/cpujul2026.html

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…